COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey
Ljungman, Per (Karolinska Institutet (Estocolm, Suècia))
de la Camara, Rafael (Hospital Universitario de la Princesa (Madrid))
Mikulska, Malgorzata (Division of Infectious Diseases. University of Genoa and Ospedale Policlinico San Martino)
Tridello, G. (Pediatric Hematology Oncology)
Aguado, Beatriz (Instituto de Investigación Hospital Universitario de la Princesa)
Zahrani, M.A. (King Abdul - Aziz Medical City)
Apperley, Jane (Centre for Haematology. Imperial College)
Berceanu, A. (Hopital Jean Minjoz)
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau)
Calbacho, Maria (Hospital Universitario 12 de Octubre (Madrid))
Ciceri, Fabio (Ospedale San Raffaele s.r.l.)
Lopez-Corral, L. (Hematology Department. Complejo Asistencial Universitario de Salamanca-IBSAL; Centro de Investigación del Cáncer-IBMCC)
Crippa, C. (Spedali Civili)
Fox, M.L. (Vall d'Hebron Institut d'Oncologia)
Grassi, A. (ASST Papa Giovanni XXIII)
Jimenez, M.J. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Demir, S.K. (HSCT unit. Demiroglu Bilim University)
Kwon, Mi (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM))
Llamas, C.V. (Hospital Universitario de Donostia (Sant Sebastià, País Basc))
Lorenzo, J.L.L. (Hospital Universitario Fundación Jiménez Díaz)
Mielke, S. (Karolinska Institutet (Estocolm, Suècia). Department of Laboratory Medicine)
Orchard, K. (University Hospital Southampton NHS Foundation Trust (Regne Unit))
Porras, R.P. (Hospital Duran i Reynals (Hospitalet del Llobregat))
Vallisa, D. (Hospital Guglielmo da Saliceto)
Xhaard, A. (Hôpital St. Louis)
Knelange, N.S. (EBMT Data Office. Department of Medical Statistics & Bioinformatics)
Cedillo, Angel (GETH Spanish Registry)
Kroeger, Nicolaus (Department of Stem cell Transplantation. University Hospital Eppendorf)
Piñana, José Luis (Hospital Clínic Universitari (València))
Styczynski, Jan (Pediatric Hematology and Oncology. University Hospital. Collegium Medicum. Nicolaus Copernicus University Torun)

Data:	2021
Resum:	This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous (n = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54. 1 years (1. 0-80. 3) for allogeneic, and 60. 6 years (7. 7-81. 6) for autologous HCT patients. The median time from HCT to COVID-19 was 15. 8 months (0. 2-292. 7) in allogeneic and 24. 6 months (−0. 9 to 350. 3) in autologous recipients. 83. 5% developed lower respiratory tract disease and 22. 5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77. 9% and 72. 1% in allogeneic and autologous recipients, respectively. Children had a survival of 93. 4%. In multivariate analysis, older age (p = 0. 02), need for ICU (p < 0. 0001) and moderate/high immunodeficiency index (p = 0. 04) increased the risk while better performance status (p = 0. 001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19.
Nota:	Altres ajuts: British Society for Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT); UK NIHR Imperial College Biomedical Research Centre.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adolescent ; Adult ; Aged ; Aged, 80 and over ; Child ; Child, Preschool ; COVID-19 ; Female ; Follow-Up Studies ; Hematologic Neoplasms ; Hematopoietic Stem Cell Transplantation ; Humans ; Infant ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; SARS-CoV-2 ; Survival Rate ; Transplantation, Homologous ; Young Adult
Publicat a:	Leukemia, Vol. 35 Núm. 10 (october 2021) , p. 2885-2894, ISSN 1476-5551

DOI: 10.1038/s41375-021-01302-5
PMID: 34079042

10 p, 1.1 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats